Research Article
PDF Zotero Mendeley EndNote BibTex Cite

Does vitamin D replacement therapy cause a regression in fatty liver disease? A case control study of comparison of vitamin D and other common therapy modalities

Year 2021, Volume 5, Issue 9, 982 - 987, 01.09.2021
https://doi.org/10.28982/josam.804878

Abstract

Background/Aim: Non-alcoholic fatty liver is quite common among modern populations, and simpler methods are researched for its early diagnosis and therapy. Studies are stating that vitamin D deficiency could play a role in the etiopathogenesis of fatty liver. This study aimed to compare the efficacy of metformin and vitamin D therapy in improving fatty liver disease. Methods: A total of 86 patients with non-alcoholic fatty liver disease were included in this case control study and classified into four groups according to the treatment received. In the study group, 23 patients were using metformin only, and 21 patients were using both metformin and vitamin D. Twenty-one patients were using vitamin D only, and 21 patients were on a diet and an exercise regimen (control group). Weight, BMI, waist circumference, fatty liver index (FLI), HOMA-IR, AST, ALT, GGT, triglyceride parameters were evaluated before and after four weeks of therapy. Results: There was a significant regression in the fatty liver disease of the patients who used both metformin and vitamin D (FLI-%5, 90 (11.1) P=0.025). Among patients who used only metformin and only vitamin D, the decrease in FLI was not significant (P>0.05); however, FLI was observed to significantly decrease in the control group (-7.30, P=0.018). The serum CRP levels were also observed to significantly decrease in the control, Met and Met-D vit groups (P=0.025, P=0.002, P=0.006, respectively). Conclusions: The combination of vitamin D and metformin therapy could positively contribute to the improvement of NAFLD in patients with vitamin D deficiency.

References

  • 1. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999;29:664‐9.
  • 2. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-8.
  • 3. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology. 1998;114:842–5.
  • 4. Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008;168(15):1609–16
  • 5. He L, Sabet A, Djedjos S, Miller R, Sun X, Hussain MA, et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell. 2009;137(4):635–46.
  • 6. Turlin B, Mendler MH, Moirand R, Guyader D, Guillygomarc’h A, Deugnier Y. Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients. Am J Clin Pathol. 2001;116:263.
  • 7. Huypens P, Quartier E, Pipeleers D, Van De Casteele M. Metformin reduces adiponectin protein expression and release in 3T3‐L1 adipocytes involving activation of AMP activated protein kinase. Eur J Pharmacol. 2005;518:90– 5.
  • 8. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin deficient mice. Nat Med. 2000;6:998-1003.
  • 9. Dasarathy J, Periyalwar P, Allampati S, Bhinder V, Hawkins C, Brandt P, et al. Hypovitaminosis D is associated with increased whole-body fat mass and greater severity of non-alcoholic fatty liver disease. Liver Int. 2014;34:118–27. doi: 10.1111/liv.12312.
  • 10. Barchetta I, Angelico F, Ben MD, Baroni MG, Pozzili P, Morini S, et al. Strong association between non-alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med. 2011;9:85.
  • 11. Targher G, Bertolini L, Scala L, et al Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2007;17(7):517–24. doi: 10.1016/j.numecd.2006.04.002.
  • 12. Eliades M, Spyrou E, Agrawal N, Lazo M, Brancati FL, Potter JJ, et al. Meta-analysis: vitamin D and non-alcoholic fatty liver disease Alimentary Pharmacology and Therapeutics. 2013;38:246-54.
  • 13. Bedogni G, Bellentani S, Miglioli L, Massuti F, Passalaqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.
  • 14. Lee SM, Jun DW, Cho YK, Jang KS, Vitamin D deficiency in non-alcoholic fatty liver disease: The chicken or the egg? Clin Nutr. 2015 Epub ahead of print.
  • 15. Cowin GJ, Jonsson JR, Bauer JD, Ash S, Ali A, Osland EJ, et.al. Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. J Magn Reson Imaging. 2008;28(4):937–45.
  • 16. Turlin B, Mendler MH, Moirand R, Guyader D, Guillygomarc’h A, Deugnier Y. Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients. Am J Clin Pathol. 2001;116:263-70.
  • 17. Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of non-alcoholic fatty liver disease. Hepatology. 2004;40:475– 83.
  • 18. Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Biomedical reports. 2013;1(1):57–64.
  • 19. Arğun D, Basim P, Uysal BB, Argun F. Association of circulating preptin with non-alcoholic fatty liver disease: A case-control study. J Surg Med. 2021;5(6):628-32.

Year 2021, Volume 5, Issue 9, 982 - 987, 01.09.2021
https://doi.org/10.28982/josam.804878

Abstract

References

  • 1. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999;29:664‐9.
  • 2. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-8.
  • 3. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology. 1998;114:842–5.
  • 4. Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008;168(15):1609–16
  • 5. He L, Sabet A, Djedjos S, Miller R, Sun X, Hussain MA, et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell. 2009;137(4):635–46.
  • 6. Turlin B, Mendler MH, Moirand R, Guyader D, Guillygomarc’h A, Deugnier Y. Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients. Am J Clin Pathol. 2001;116:263.
  • 7. Huypens P, Quartier E, Pipeleers D, Van De Casteele M. Metformin reduces adiponectin protein expression and release in 3T3‐L1 adipocytes involving activation of AMP activated protein kinase. Eur J Pharmacol. 2005;518:90– 5.
  • 8. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin deficient mice. Nat Med. 2000;6:998-1003.
  • 9. Dasarathy J, Periyalwar P, Allampati S, Bhinder V, Hawkins C, Brandt P, et al. Hypovitaminosis D is associated with increased whole-body fat mass and greater severity of non-alcoholic fatty liver disease. Liver Int. 2014;34:118–27. doi: 10.1111/liv.12312.
  • 10. Barchetta I, Angelico F, Ben MD, Baroni MG, Pozzili P, Morini S, et al. Strong association between non-alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med. 2011;9:85.
  • 11. Targher G, Bertolini L, Scala L, et al Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2007;17(7):517–24. doi: 10.1016/j.numecd.2006.04.002.
  • 12. Eliades M, Spyrou E, Agrawal N, Lazo M, Brancati FL, Potter JJ, et al. Meta-analysis: vitamin D and non-alcoholic fatty liver disease Alimentary Pharmacology and Therapeutics. 2013;38:246-54.
  • 13. Bedogni G, Bellentani S, Miglioli L, Massuti F, Passalaqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.
  • 14. Lee SM, Jun DW, Cho YK, Jang KS, Vitamin D deficiency in non-alcoholic fatty liver disease: The chicken or the egg? Clin Nutr. 2015 Epub ahead of print.
  • 15. Cowin GJ, Jonsson JR, Bauer JD, Ash S, Ali A, Osland EJ, et.al. Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. J Magn Reson Imaging. 2008;28(4):937–45.
  • 16. Turlin B, Mendler MH, Moirand R, Guyader D, Guillygomarc’h A, Deugnier Y. Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients. Am J Clin Pathol. 2001;116:263-70.
  • 17. Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of non-alcoholic fatty liver disease. Hepatology. 2004;40:475– 83.
  • 18. Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Biomedical reports. 2013;1(1):57–64.
  • 19. Arğun D, Basim P, Uysal BB, Argun F. Association of circulating preptin with non-alcoholic fatty liver disease: A case-control study. J Surg Med. 2021;5(6):628-32.

Details

Primary Language English
Subjects Medicine
Journal Section Research article
Authors

Vusal ABDURAHMANOV This is me
YEDİTEPE ÜNİVERSİTESİ, TIP FAKÜLTESİ
0000-0002-8229-9784
Türkiye


Arzu GÜNTÜRK (Primary Author)
YEDİTEPE UNIVERSITY
0000-0002-1941-8699
Türkiye


Fatma KARTUFAN This is me
YEDİTEPE UNIVERSITY
0000-0002-5592-2366
Türkiye


Rahman NURMUHAMMEDOV This is me
YEDİTEPE UNIVERSITY
0000-0002-7345-6741
Türkiye


Yaşar KÜÇÜKARDALI This is me
YEDİTEPE UNIVERSITY
0000-0002-8719-8886
Türkiye

Publication Date September 1, 2021
Published in Issue Year 2021, Volume 5, Issue 9

Cite

Bibtex @research article { josam804878, journal = {Journal of Surgery and Medicine}, issn = {}, eissn = {2602-2079}, address = {jsurgmed@gmail.com}, publisher = {Fatih BAŞAK}, year = {2021}, volume = {5}, pages = {982 - 987}, doi = {10.28982/josam.804878}, title = {Does vitamin D replacement therapy cause a regression in fatty liver disease? A case control study of comparison of vitamin D and other common therapy modalities}, key = {cite}, author = {Abdurahmanov, Vusal and Güntürk, Arzu and Kartufan, Fatma and Nurmuhammedov, Rahman and Küçükardalı, Yaşar} }
APA Abdurahmanov, V. , Güntürk, A. , Kartufan, F. , Nurmuhammedov, R. & Küçükardalı, Y. (2021). Does vitamin D replacement therapy cause a regression in fatty liver disease? A case control study of comparison of vitamin D and other common therapy modalities . Journal of Surgery and Medicine , 5 (9) , 982-987 . DOI: 10.28982/josam.804878
MLA Abdurahmanov, V. , Güntürk, A. , Kartufan, F. , Nurmuhammedov, R. , Küçükardalı, Y. "Does vitamin D replacement therapy cause a regression in fatty liver disease? A case control study of comparison of vitamin D and other common therapy modalities" . Journal of Surgery and Medicine 5 (2021 ): 982-987 <http://jsurgmed.com/en/pub/issue/64812/804878>
Chicago Abdurahmanov, V. , Güntürk, A. , Kartufan, F. , Nurmuhammedov, R. , Küçükardalı, Y. "Does vitamin D replacement therapy cause a regression in fatty liver disease? A case control study of comparison of vitamin D and other common therapy modalities". Journal of Surgery and Medicine 5 (2021 ): 982-987
RIS TY - JOUR T1 - Does vitamin D replacement therapy cause a regression in fatty liver disease? A case control study of comparison of vitamin D and other common therapy modalities AU - Vusal Abdurahmanov , Arzu Güntürk , Fatma Kartufan , Rahman Nurmuhammedov , Yaşar Küçükardalı Y1 - 2021 PY - 2021 N1 - doi: 10.28982/josam.804878 DO - 10.28982/josam.804878 T2 - Journal of Surgery and Medicine JF - Journal JO - JOR SP - 982 EP - 987 VL - 5 IS - 9 SN - -2602-2079 M3 - doi: 10.28982/josam.804878 UR - https://doi.org/10.28982/josam.804878 Y2 - 2021 ER -
EndNote %0 Journal of Surgery and Medicine Does vitamin D replacement therapy cause a regression in fatty liver disease? A case control study of comparison of vitamin D and other common therapy modalities %A Vusal Abdurahmanov , Arzu Güntürk , Fatma Kartufan , Rahman Nurmuhammedov , Yaşar Küçükardalı %T Does vitamin D replacement therapy cause a regression in fatty liver disease? A case control study of comparison of vitamin D and other common therapy modalities %D 2021 %J Journal of Surgery and Medicine %P -2602-2079 %V 5 %N 9 %R doi: 10.28982/josam.804878 %U 10.28982/josam.804878
ISNAD Abdurahmanov, Vusal , Güntürk, Arzu , Kartufan, Fatma , Nurmuhammedov, Rahman , Küçükardalı, Yaşar . "Does vitamin D replacement therapy cause a regression in fatty liver disease? A case control study of comparison of vitamin D and other common therapy modalities". Journal of Surgery and Medicine 5 / 9 (September 2021): 982-987 . https://doi.org/10.28982/josam.804878
AMA Abdurahmanov V. , Güntürk A. , Kartufan F. , Nurmuhammedov R. , Küçükardalı Y. Does vitamin D replacement therapy cause a regression in fatty liver disease? A case control study of comparison of vitamin D and other common therapy modalities. J Surg Med. 2021; 5(9): 982-987.
Vancouver Abdurahmanov V. , Güntürk A. , Kartufan F. , Nurmuhammedov R. , Küçükardalı Y. Does vitamin D replacement therapy cause a regression in fatty liver disease? A case control study of comparison of vitamin D and other common therapy modalities. Journal of Surgery and Medicine. 2021; 5(9): 982-987.
IEEE V. Abdurahmanov , A. Güntürk , F. Kartufan , R. Nurmuhammedov and Y. Küçükardalı , "Does vitamin D replacement therapy cause a regression in fatty liver disease? A case control study of comparison of vitamin D and other common therapy modalities", Journal of Surgery and Medicine, vol. 5, no. 9, pp. 982-987, Sep. 2021, doi:10.28982/josam.804878

The DNS issue is resolved. jsurgmed.com and current publication are fully accessible.

To use the submission system properly, please use one of the following browsers, Chrome or Firefox, with the latest updates.
If you experience problems, it may be necessary to clear the browser cache and history; and disable blocker extensions, i.e., uBlock, of the browsers
Mobile phones are not recommended, please use a personal computer.